

Published in final edited form as:

Am J Transplant. 2022 July; 22(7): 1935–1936. doi:10.1111/ajt.17011.

Kidney Xenotransplantation in a Brain-Dead Donor: Glass halffull or half-empty?

Leonardo V. Riella^{1,2,3}, James F. Markmann^{1,3}, Joren C. Madsen^{1,3}, Ivy A. Rosales^{1,4}, Robert B. Colvin^{1,4}, Tatsuo Kawai^{1,3}, Richard N. Pierson III^{1,3}

¹Center for Transplantation Sciences, Massachusetts General Hospital, and Harvard Medical School, Boston, MA

²Department of Medicine, Massachusetts General Hospital, and Harvard Medical School, Boston, MA

³Department of Surgery, Massachusetts General Hospital, and Harvard Medical School, Boston, MA

⁴Department of Pathology, Massachusetts General Hospital, and Harvard Medical School, Boston, MA

Keywords

translational research; science; clinical research; practice; immunobiology; xenotransplantation; solid organ transplantation; xenoantigen; xenoantibody; kidney (allograft) function; dysfunction

We congratulate Dr. Locke and colleagues for their contributions to xenotransplant biology through their manuscript reporting the results of a genetically engineered (GE) porcine kidney transplanted into a brain-dead human (1). We join the research team in expressing gratitude to the family of the donor for allowing their loved one to participate in such important research. Here we offer our interpretation of the data presented and recommendations for next steps.

The reported case demonstrates the surgical feasibility of intra-abdominal bilateral sequential kidney xenotransplantation. Based on the clinical appearance of the kidney xenografts and the initial production of urine by the first kidney, the authors conclude that the pair of 'ten-GE' pig kidneys were protected from hyperacute rejection, as predicted based on extensive prior work with GE pigs in nonhuman primate recipients (NHP) (2-3). However, the cause of the rapid appearance of thrombotic microangiopathy on the first xenograft biopsy and the absence of significant creatinine clearance over the subsequent three days following the transplant needs to be addressed.

Thrombotic microangiopathy (TMA) in the reperfusion biopsy at POD1 could be a sign of antibody-mediated xenograft rejection; however the negative historical crossmatch argues against this interpretation. Distinguishing TMA from antibody-mediated rejection (AMR)

^{*}Corresponding author: Leonardo V. Riella, MD, PhD, FASN, lriella@mgh.harvard.edu.

Riella et al. Page 2

remains a challenge in xenotransplantation (4). The patient exhibited systemic evidence of TMA before nephrectomy, as indicated by an elevated D-dimer, prolonged prothrombin and partial thromboplastin times, and abnormal kidney function, presumably attributable to the inflamed, hypercoagulable state caused by traumatic brain injury (TBI) (5). While marked thrombocytopenia and anemia are also compatible with the consumptive coagulopathy observed occasionally in NHP renal and heart recipients of pig xenografts, these typically arise later after those transplants. Because there was rapid clearing of the lesions on repeated biopsies with reduction in glomerular thrombi reported at POD3, we believe that the lesions are unlikely to be due to antibody mediated rejection and more likely due to the hypercoagulable state of the recipient.

To promote a wider understanding of the results of these initial and future limited experiments, we encourage these and other authors to include high-resolution images and additional routine diagnostic stains (for fibrin and platelets, e.g.) in future reports, or in supplemental material with digital images placed on a public server, analogous to how genomic data are publicly curated. Lastly, standard analysis should include electron microscopy, as is routine in clinical kidney biopsies, to assess the presence and extent of TMA and the status of the endothelium and podocytes.

While Porrett et al. showed that the right kidney produced more than 500 ml of urine within 24 hours of transplant, the clearance function of the transplanted kidneys was effectively absent, as evidenced by the rising creatinine and low concentration of creatinine in the urine. The cause of the persistent kidney dysfunction was not clarified; the only reported histologic correlate was acute tubular injury (ATI). Impaired kidney function due to ATI could have been aggravated by hemodynamic instability of the decedent, who demonstrated an increased pressor requirement (dopamine and phenylephrine) and steadily declining MAPs. To separate the contribution of the physiologic environment of the brain-dead donor from pathophysiology ascribable to the potentially pro-inflammatory pig-human interface, and to thus better assess the compatibility of the GE pig kidney with humans, we suggest the next step should be to transplant the GE pig kidney into a dialysis-dependent, otherwise stable ESKD patients (with no living donor and on the bottom of the waiting list).

Finally, most NHP xenotransplant studies have demonstrated that the calcineurin-inhibitor-based immunosuppression prevalently used in humans is inferior to costimulation pathway blockade to prevent organ xenograft rejection. Costimulation blockade of CD40-CD40L pathway was required for long-term graft survival in preclinical heart and kidney studies (6), and was used by the Maryland group in their recent heart xenograft case. Indeed, Kawai and colleagues have kidney xenotransplants surviving over one year without rejection or TMA in nonhuman primates (manuscript in preparation). Unfortunately, the 3-day duration of follow-up in the current report does not contribute to our evidence base in this regard.

Funding Institutions:

Foundation for the National Institutes of Health, (Grant / Award Number: 'U01 AI146248, UO1 AI153612, U19 AI 090959')

Riella et al. Page 3

COI statement:

The authors have no financial conflicts of interest to declare with respect to this communication. JFM, JCM, and RNP have been supported by research funding from eGenesis, JFM and RBC are consultants to eGenesis, and Revivicor provides animals in support of RNP's research. JFM (U01 AI146248) and RNP (U01 AI153612, U19 AI 090959) are supported by NIH grants for work in the field. RNP is Chair of the Ethics Committee of the International Xenotransplantation Association (IXA), a Section within the Transplantation Society; views expressed here are communicated outside of that role.

References

- Porrett PM, Orandi BJ, Kumar V, Houp J, Anderson D, Cozette Killian A, Hauptfeld-Dolejsek V, Martin DE, Macedon S, Budd N, Stegner KL, Dandro A, Kokkinaki M, Kuravi KV, Reed RD, Fatima H, Killian JT Jr, Baker G, Perry J, Wright ED, Cheung MD, Erman EN, Kraebber K, Gamblin T, Guy L, George JF, Ayares D, Locke JE. First clinical-grade porcine kidney xenotransplant using a human decedent model. Am J Transplant. 2022 Jan 20. doi: 10.1111/ ajt.16930. Online ahead of print.
- 2. Iwase H, Hara H, Ezzelarab M, Li T, Zhang Z, Gao B, Liu H, Long C, Wang Y, Cassano A, Klein E, Phelps C, Ayares D, Humar A, Wijkstrom M, Cooper DKC. Immunological and physiologic observations in baboons with life-supporting genetically-engineered pig kidney grafts. Xenotransplantation. 2017;24: doi: 10.1111/xen.12293
- 3. Ma D, Hirose T, Lassiter G, Sasaki H, Rosales I, Coe TM, Rickert CG, Matheson R, Colvin RB, Qin W, Kan Y, Layer JV, Paragas VB, Stiede K, Hall KC, Youd ME, Queiroz LM, Westlin WF, Curtis M, Yang L, Markmann JF, Kawai T. Kidney transplantation from triple-knockout pigs expressing multiple human proteins in cynomolgus macaques. Am J Transplant. 2022 Jan;22(1):46–57. doi: 10.1111/ajt.16780. Epub 2021 Aug 31. [PubMed: 34331749]
- 4. Rosales IA, Colvin RB. The pathology of solid organ xenotransplantation. Curr Opin Organ Transplant 2019;24(5):535–542. [PubMed: 31348015]
- 5. Lisman T, Leuvenink HG, Porte RJ, Ploeg RJ. Activation of hemostasis in brain dead organ donors: an observational study. J Thromb Haemost 2011;9(10):1959–1965. [PubMed: 21762465]
- 6. Bikhet MH, Iwase H, Yamamoto T, Jagdale A, Foote JB, Ezzelarab M, Anderson DJ, Locke JE, Eckhoff DE, Hara H, Cooper DKC. What therapeutic regimen will be optimal for initial clinical trials of pig organ transplantation? Transplantation. 2021 Jan 27. Doi: 10.1097/ TP.00000000003622. Online ahead of print.